WUHAN HITECK BIOPHARMACEUTICAL CO., LTD
HITECK bio is a high-tech biopharmaceutical enterprise with the goal of building an excellent innovative biopharmaceutical enterprise in China. It was listed on the main board of Shenzhen Stock Exchange on August 8, 2017 (stock abbreviation: HITECK bio, stock code: 300683)...
The company is based on the R & D and production of drugs in the field of nervous system and oncology
A national class I biological new drug, mouse nerve growth factor for injection (Jinlujie), and a class I genetic engineering biological new drug, recombinant mutant human tumor necrosis factor related apoptosis inducing ligand (CPT) have been put on the market. The phase III clinical blinding work has been completed and the application for production approval is in the preparation stage.
INNOVATIVE RESEARCH AND DEVELOPMENT
The company is a high-tech enterprise in Hubei Province. There are post doctoral mobile workstations approved by the Ministry of human resources and social security of the people's Republic of China, and "Hubei rare disease drug engineering technology research center" and "Hubei high tech innovative enterprise" approved by the provincial science and technology department. Five basic technology platforms have been established, and pilot bases have been established to promote the industrialization of relevant achievements and efficient transformation to the market.